Revvity stock reaction and recent performance snapshot

Revvity (RVTY) stock has come under pressure recently, with the share price down about 2.5% over the past day and roughly 7% over the past week, drawing attention to its current valuation.

Over the past month, the stock has been broadly flat, while over the past 3 months it has declined about 2.1%. Year to date, the move is a decline of around 4.3%, with a total return of about 1.1% over the past year.

The recent share price slide to US$93.97, along with a 1-year share price return that trails the 1-year total shareholder return of 1.05%, suggests sentiment has softened even as dividends slightly cushion longer term performance.

If this stock’s recent pullback has you reassessing your watchlist, it could be a good moment to widen your search using our screener for 32 healthcare AI stocks.

With Revvity trading around US$93.97 and metrics hinting at an intrinsic discount, the key question for you is simple: is this recent weakness setting up a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 21.4% Undervalued

Revvity's most followed narrative pegs fair value at $119.56, well above the last close at $93.97, suggesting a valuation gap that depends on future earnings power.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Curious what kind of revenue trajectory, margin profile, and earnings multiple need to align to support that fair value gap? The full narrative outlines a detailed path built on recurring software revenue, diagnostics demand, and a higher profitability base that aims to justify a richer valuation over time.

Result: Fair Value of $119.56 (UNDERVALUED)

However, investors also need to keep an eye on policy and reimbursement changes in key markets, as well as any prolonged funding pressure on academic and government customers.

Another angle on valuation

While Simply Wall St's DCF model suggests Revvity is trading at a 31.8% discount to an estimated future cash flow value of $137.71, its current P/E of 43.8x is far above a fair ratio of 20.9x and above both peer and industry averages. Which signal do you consider more important for your own thesis?

Next Steps

With mixed signals on value, risk, and reward, do you feel the clock is ticking to firm up your own view? Take a closer look at the underlying data, pressure test your thesis, and then weigh up the balance of 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you only focus on one stock, you risk missing opportunities elsewhere, so keep building out your watchlist with ideas that match your style and risk comfort.

• Spot potential early movers by scanning 27 elite penny stocks with strong financials that already show stronger financial footing than many peers.
• Zero in on quality at a discount by reviewing 51 high quality undervalued stocks that pair solid fundamentals with pricing that may look appealing.
• Prioritise resilience by checking 65 resilient stocks with low risk scores where balance sheets and risk scores aim to keep surprises to a minimum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.